Date:5/3/2011

y to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the cost of obligations under the Company's benefit plans; and pending accounting pronouncements.  These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today.  These risks and uncertainties also may result in changes to the Company's business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses.  Additional information may be obtained by reviewing the information set forth in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended September 30, 2010, and other reports filed by the Company from time to time with the Securities and Exchange Commission.Financial Tables FollowSecond Fiscal Quarter 2011 Financial Highlights(unaudited, amounts in thousands, except per share data)Three Months EndedSix Months EndedMarch 31,March 31,2011

20102011

2010Net revenues

$   32,327

$   31,806$   60,765

$   59,040Costs and expenses:   Cost of sales

11,604

11,81922,687

21,975   Selling, general and administrative

8,728

8,40817,859

16,212   Acquisition and reorganization costs

115

143212

1,660Costs and expenses

20,447

20,37040,758

39,847Operating income

11,880

11,43620,007

19,193Other income, net

'/>"/>

SOURCE Landauer, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Landauer, Inc. Appoints Two New Members to Board of Directors
2. Cynosure Reports Financial Results for the First Quarter of 2011
3. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
4. VIVUS Reports First Quarter 2011 Financial Results
5. Dendreon Reports First Quarter 2011 Financial Results
6. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
7. Nektar Therapeutics Reports First Quarter 2011 Financial Results
8. Veteran Wall Street Securities Analyst Reports on Health Discovery Corporation
9. China Green Material Technologies, Inc. Reports 2010 Financial Results
10. GeneLink Reports Denial of Appeal
11. GeneLink Reports 2010 Results